Stratec (SBS) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Consolidated sales increased by 12.0% year-over-year to €60.4 million, driven by strong demand for software solutions and product lifecycle management.
Adjusted EBIT margin rose by 350 basis points to 8.9% compared to Q1/2024, reflecting improved profitability.
Spare Parts and Consumables division posted double-digit growth, while Systems business saw a moderate sales decline.
New cooperations and advanced negotiations for extending product lifecycles and cybersecurity solutions supported growth.
Financial highlights
Adjusted EBITDA increased to €9.3 million (Q1/2024: €6.6 million); margin improved to 15.4%.
Adjusted EBIT rose to €5.4 million (Q1/2024: €2.9 million), up 83.6% year-over-year.
Adjusted consolidated net income reached €3.2 million, nearly tripling from €1.1 million in Q1/2024.
Adjusted EPS was €0.26, up from €0.09; reported EPS was €0.12, up from €0.02.
Figures adjusted to exclude PPA amortization and non-recurring items such as advisory and restructuring expenses.
Outlook and guidance
2025 guidance confirmed: constant-currency sales growth expected in low to mid single-digit percentage range.
Adjusted EBIT margin forecasted at 10.0% to 12.0% for 2025 (2024: 13.0%).
Significant earnings growth from Development and Services expected in Q4/2025.
Investments in property, plant, equipment, and intangibles budgeted at 8.0% to 10.0% of sales.
Latest events from Stratec
- Margins and cash flow improved despite lower sales; 2024 guidance remains unchanged.SBS
Q2 20241 Feb 2026 - Sales down 6.1% Y/Y; margins stable; Q4 rebound expected from new orders and deliveries.SBS
Q3 202418 Jan 2026 - Stable margins and recurring revenues support growth as innovation and M&A drive recovery.SBS
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Margin and cash flow gains in 2024; 2025 to see modest growth and margin normalization.SBS
Q4 202426 Nov 2025 - Sales up 5.2% YoY; margins down on FX; H2 to see sales and margin improvement.SBS
Q2 202523 Nov 2025 - Consumables and service parts now lead revenue, with growth set to return as replacement cycles accelerate.SBS
Health Care Conference14 Nov 2025 - Sales up 2.5% at constant currency, but margins and net income declined amid supply chain challenges.SBS
Q3 20257 Nov 2025 - Profitability and cash flow improved despite lower sales, with a focus on high-growth diagnostics markets.SBS
Investor Presentation27 Jun 2025 - Recurring revenues and cash flow improved despite lower sales and postponed deliveries in 2024.SBS
Investor Presentation27 Jun 2025